Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 9, 2023, reports on Precision BioSciences, Inc.'s (DTIL) preliminary unaudited cash balance as of December 31, 2022, and outlines operational achievements for the full year 2022. The company is an emerging growth company focused on allogeneic CAR T-cell therapies and in vivo gene editing.
Key Financial Metrics
- Cash Position: The filing references a press release detailing the preliminary unaudited cash balance as of December 31, 2022, but does not explicitly state the specific dollar amount in the text provided.
- Liquidity Runway: Management believes existing cash, cash equivalents, expected operational receipts, and available credit are sufficient to fund operating expenses and capital expenditures into 2025.
- Capital Additions: In 2022, the company added $125 million to its balance sheet.
- Revenue/Profit: The filing text does not provide specific revenue, profit, or margin figures for the period.
Material Changes and Operational Highlights
- Collaborations: Entered a new in vivo gene editing collaboration with Novartis focused on sickle cell disease and beta thalassemia.
- Regulatory Feedback: Received FDA Type C feedback on CMC processes for azercabtagene zapreleucel (azer-cel), allowing continued enrollment in the Phase 1/2a trial for relapsed/refractory non-Hodgkin lymphoma.
- Clinical Data: In the latest Phase 1b cohort (n=12, data as of May 31, 2022), azer-cel achieved a 100% overall response rate and 73% complete response rate. No Grade 3+ cytokine release syndrome was observed.
- Portfolio Prioritization: Ceased pursuit of the PBGENE-PCSK9 program for familial hypercholesterolemia. Decided to seek a partner for the PBGENE-PH1 program rather than developing it independently.
Guidance, Outlook, and Risks
2023 Priorities and Milestones:
- Azer-cel: Progress to a Phase 2 decision point for NHL subjects relapsed after autologous CAR T; present clinical update in Q1 2023.
- HBV Program: Advance PBGENE-HBV to final clinical candidate with a target CTA/IND filing in 2024.
- OTC Program: Advance ARCUS-mediated gene insertion for ornithine transcarbamylase deficiency; partner iECURE targets CTA/IND filing in H2 2023.
- Partnered Programs: Progress Novartis and Lilly programs (DMD, sickle cell) toward IND.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding the ability to become profitable, secure funding, achieve clinical milestones, and navigate regulatory landscapes. Specific risks include dependence on ARCUS technology, competition, manufacturing challenges, and potential litigation.
Investor Verification Checklist
- Verify the exact preliminary cash balance as of December 31, 2022, by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the specific terms and milestone payments associated with the new Novartis collaboration.
- Monitor the Q1 2023 clinical update for azer-cel to validate the 100% overall response rate and safety profile in a larger cohort.
- Track the timeline for the PBGENE-HBV CTA/IND filing targeted for 2024.
- Assess the status of the search for a partner for the PBGENE-PH1 program.